Genotype and Allele Frequency of in Turkish Patients with Major Depressive Disorder

Overview

Journal Turk J Pharm Sci

Specialty Pharmacology

Date 2020 May 27

PMID 32454661

Authors

Zuhal Uckun

Bora Baskak

Hatice Ozdemir

Erguvan Tugba Ozel-Kizil

Halise Devrimci-Ozguven

Halit Sinan Suzen

Affiliations

Soon will be listed here.

Abstract

Objectives: Genetic polymorphisms may help for individualized drug dosing and improved therapeutics. CYP3A4 is responsible for the metabolism of more than 50% of the commonly used drugs and metabolizes typical antipsychotic medications and antidepressant drugs. The objective of the study was to assess the genotype and allele frequencies of in Turkish patients with major depressive disorder receiving any SSRIs and to compare these results with the frequencies of other ethnic groups.

Materials And Methods: Genotyping analyses of was conducted on 84 Turkish patients using the PCR-RFLP technique.

Results: The allele frequencies were found as 0.982 (A) and 0.018 (G) for . The genotype frequencies were determined as 0.976 (AA), 0.012 (AG), and 0.012 (GG). The genotype frequencies were consistent with the Hardy-Weinberg equilibrium.

Conclusion: The genotype and allele frequencies of were determined to be low in Turkish patients with major depressive disorder receiving SSRIs. Furthermore, the results of the study were compared with those of other ethnic groups and they displayed pronounced differences among other ethnic groups, especially black subjects.

References

Walker A, Jaffe J, Gunasegaram S, Cummings S, Huang C, Chern H . Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat. 2000; 12(4):289. View

Sata F, Sapone A, Elizondo G, Stocker P, Miller V, Zheng W . CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000; 67(1):48-56. DOI: 10.1067/mcp.2000.104391. View

Salameh G, Al Hadidi K, El Khateeb M . Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol. 2012; 34(1):23-33. DOI: 10.1016/j.etap.2012.01.006. View

Rebbeck T, Jaffe J, Walker A, Wein A, Malkowicz S . Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998; 90(16):1225-9. DOI: 10.1093/jnci/90.16.1225. View

Ruzilawati A, Mohd Suhaimi A, Gan S . Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta. 2007; 383(1-2):158-62. DOI: 10.1016/j.cca.2007.05.004. View

Garsa A, McLeod H, Marsh S . CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005; 6:19. PMC: 1142317. DOI: 10.1186/1471-2350-6-19. View

McDaniel D, Thurber T, Lewis-Traylor A, Berry C, Barber W, Zhou X . Differential association of cytochrome P450 3A4 genotypes with onsets of breast tumors in African American versus Caucasian patients. J Investig Med. 2011; 59(7):1096-103. DOI: 10.2310/JIM.0b013e3182277e3b. View

Gurocak S, Konac E, Ure I, Senol C, Onen I, Sozen S . The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder. Dis Markers. 2015; 2015:732686. PMC: 4488149. DOI: 10.1155/2015/732686. View

Gervasini G, Garcia-Martin E, Ladero J, Pizarro R, Sastre J, Martinez C . Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007; 7:118. PMC: 1931602. DOI: 10.1186/1471-2407-7-118. View

10.

Veiga M, Asimus S, Ferreira P, Martins J, Cavaco I, Ribeiro V . Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol. 2008; 65(4):355-63. DOI: 10.1007/s00228-008-0573-8. View

11.

Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y . Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1999; 91(18):1587-90. DOI: 10.1093/jnci/91.18.1587. View

12.

Jin T, Yang H, Zhang J, Yunus Z, Sun Q, Geng T . Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. Int J Clin Exp Pathol. 2015; 8(6):7083-91. PMC: 4525935. View

13.

Dogruer D, Tug E, Bes C, Soy M . Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res. 2013; 12(3):3521-8. DOI: 10.4238/2013.January.24.2. View

14.

Kumar V, Singh S, Yadav C, Ahmed R, Gupta S, Pasha S . CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol. 2011; 29(2):126-30. DOI: 10.1016/j.etap.2009.12.001. View

15.

Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T . Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2003; 23(1):100. DOI: 10.1002/humu.9210. View

16.

van Schaik R, de Wildt S, van Iperen N, Uitterlinden A, van den Anker J, Lindemans J . CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem. 2000; 46(11):1834-6. View

17.

Dally H, Bartsch H, Jager B, Edler L, Schmezer P, Spiegelhalder B . Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 2004; 207(1):95-9. DOI: 10.1016/j.canlet.2003.12.011. View

18.

Bangsi D, Zhou J, Sun Y, Patel N, Darga L, Heilbrun L . Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006; 24(1):21-7. DOI: 10.1016/j.urolonc.2005.09.005. View

19.

Huang S, Goodsaid F, Rahman A, Frueh F, Lesko L . Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods. 2009; 16(2-3):89-99. DOI: 10.1080/15376520600558333. View

20.

Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X . Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011; 56(6):415-22. DOI: 10.1038/jhg.2011.30. View